AlloVir, Inc.

Informe acción NasdaqCM:ALVR

Capitalización de mercado: US$62.9m

AlloVir Dirección

Dirección controles de criterios 3/4

El CEO de AlloVir es Diana Brainard , nombrado en May 2021, tiene una permanencia de 3.5 años. compensación anual total es $6.06M, compuesta por 10.3% salario y 89.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.31% de las acciones de la empresa, por valor de $193.69K. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 4.3 años, respectivamente.

Información clave

Diana Brainard

Chief Executive Officer (CEO)

US$6.1m

Compensación total

Porcentaje del salario del CEO10.3%
Permanencia del CEO3.5yrs
Participación del CEO0.3%
Permanencia media de la dirección5.8yrs
Promedio de permanencia en la Junta Directiva4.3yrs

Actualizaciones recientes de la dirección

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Diana Brainard en comparación con los beneficios de AlloVir?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$180m

Dec 31 2023US$6mUS$623k

-US$190m

Sep 30 2023n/an/a

-US$169m

Jun 30 2023n/an/a

-US$167m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$9mUS$605k

-US$169m

Sep 30 2022n/an/a

-US$189m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$15mUS$365k

-US$172m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$117m

Mar 31 2021n/an/a

-US$91m

Dec 31 2020US$597kn/a

-US$70m

Compensación vs. Mercado: La compensación total de Diana($USD6.06M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).

Compensación vs. Ingresos: La compensación de Diana ha sido consistente con los resultados de la empresa en el último año.


CEO

Diana Brainard (52 yo)

3.5yrs

Permanencia

US$6,056,943

Compensación

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
David Hallal
Executive Chairman of the Board6.2yrsUS$347.00k2.45%
$ 1.5m
Diana Brainard
CEO & Director3.5yrsUS$6.06m0.31%
$ 193.7k
Vikas Sinha
President5.8yrsUS$2.94m0.85%
$ 536.0k
Edward Miller
General Counsel & Secretary5.8yrsUS$1.89m0.38%
$ 236.4k
Brett Hagen
Chief Accounting Officer5.8yrssin datos0.012%
$ 7.8k
Ann Leen
Chief Scientific Officer11.8yrssin datossin datos
Cintia Piccina
Chief Commercial Officer1.4yrssin datossin datos

5.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALVR es experimentado (5.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
David Hallal
Executive Chairman of the Board6.2yrsUS$347.00k2.45%
$ 1.5m
Diana Brainard
CEO & Director4.3yrsUS$6.06m0.31%
$ 193.7k
Vikas Sinha
President5.8yrsUS$2.94m0.85%
$ 536.0k
John Mellors
Member of the Scientific Advisory Board1.8yrssin datossin datos
Malcolm Brenner
Independent Non-Executive Director12.8yrsUS$196.28k0.20%
$ 126.0k
Jeffrey Bornstein
Independent Non-Executive Director4.3yrsUS$211.78k0.066%
$ 41.4k
Michael Boeckh
Member of Scientific Advisory Board1.8yrssin datossin datos
John DiPersio
Member of Scientific Advisory Board1.8yrssin datossin datos
Anil Chandraker
Member of Scientific Advisory Board1.8yrssin datossin datos
Morana Jovan-Embiricos
Independent Non-Executive Director5.5yrsUS$209.28k8.66%
$ 5.4m
Shawn Tomasello
Independent Director2.7yrsUS$200.73k0.031%
$ 19.3k
Juan Vera
Non-Executive Director10.8yrsUS$187.00k2.08%
$ 1.3m

4.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de ALVR se considera experimentada (4.3 años de antigüedad promedio).